Company profile: GeoVax
1.1 - Company Overview
Company description
- Provider of vaccine and cancer therapy R&D, including GEO-CM04S1, a next‑generation Covid‑19 vaccine in Phase 2 for immunocompromised patients and as a heterologous booster; Gedeptin for advanced head and neck cancer (Phase 1/2 enrollment completed); preventive vaccines for Mpox, smallpox, Ebola (Zaire/Sudan), Marburg, malaria and Zika; an MVA vaccine platform using Modified Vaccinia Ankara; and GDEPT technology for solid tumors.
Products and services
- MVA vaccine platform: A vector-based framework utilizing Modified Vaccinia Ankara to engineer vaccines for infectious diseases and to construct cancer immunotherapies across diversified program areas
- GEO-CM04S1: A clinical-stage, next-generation COVID-19 vaccine in Phase 2 trials that targets immunocompromised patient populations and is being evaluated as a heterologous booster
- Preventive vaccines against infectious diseases: Pipeline-scale programs developing vaccines for Mpox, smallpox, Ebola Zaire, Ebola Sudan, Marburg, malaria, and Zika virus, expanding pathogen coverage across high-consequence indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GeoVax
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
Clever Culture Systems
HQ: Switzerland
Website
- Description: Provider of intelligent image analysis solutions using artificial intelligence, including APAS Independence for automated microbial environmental monitoring with digital records, audit trails, standardized workflows and reduced human error, and MRSA and VRE Analysis Modules that automate detection on chromogenic media for efficient infection control by reporting negatives and triaging positives for review.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clever Culture Systems company profile →
ANA Therapeutics
HQ: United States
Website
- Description: Provider of biotech therapeutics developing a novel coronavirus vaccine and niclosamide-based treatments to enable medical practitioners to treat patients with COVID-19; founded in 2020 and headquartered in Foster City, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANA Therapeutics company profile →
Pherecydes Pharma
HQ: France
Website
- Description: Provider of innovative biotechnology focused on developing personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and has launched a multicenter European phage therapy trial to evaluate treatment on infected burn wounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherecydes Pharma company profile →
Leyden Labs
HQ: The Netherlands
Website
- Description: Provider of a mucosal immunity platform targeting commonalities of viral families to protect against known and future respiratory viruses, offering intranasal antibody sprays for immediate antiviral protection, including PanFlu nasal spray (CR9114 antibody) for broad influenza protection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leyden Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GeoVax
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GeoVax
2.2 - Growth funds investing in similar companies to GeoVax
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GeoVax
4.2 - Public trading comparable groups for GeoVax
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →